Close

Drug Research

COVID-19 Fourth Jab Reduces Death By 72% In The Elderly

According to a recent study conducted by Tel Aviv University and Ben Gurion University of the Negev in conjunction with the Israeli Ministry of Health, the fourth COVID-19 vaccination is effective in preventing the Omicron form from infecting the...

As A Side Effect, EU Lists Allergies To Novavax COVID Shots

The COVID-19 vaccine from Novavax Inc. may cause serious allergic reactions, according to the European Medicines Agency. The vaccine's product label in the United States forbids giving the shot to anyone who has had a history of acute toxicity to...

No Rush In Indian Generic Drug Firms To Offer COVID Products

Indian generic drugmakers are delaying more investments in COVID-related drugs after making gains in the last two years, according to certain pharmaceutical industry insiders. BDR Pharmaceuticals' managing director, Dharmesh Shah, stated that when COVID-19 cases start to decline, his company is...

Genomic Studies Utilize Scale As Clinical Utility Catches Up

An innovative system for monitoring chromosomal fragility and copy number alterations in particularly lethal tumours was described earlier this July by researchers from Cambridge University and the National Cancer Research Center in Madrid. Researchers believe this is the first time...

Novavax COVID-19 Vaccine Is Fourth US Option Now Available

As infections in the U.S. continue to be at high levels, the Food and Drug Administration on 13th July approved a fourth vaccination for COVID-19 prevention, authorising Novavax's coronavirus jab for emergency use in adults. The Maryland-based drugmaker's early results on...

Alice – a tireless hero in the fight against Covid-19

Aspen successfully expands CMO activities with filling equipment from Syntegon At first sight, anesthetics and vaccines don’t have much in common: while the first have a narcotic effect, the latter prevent diseases from breaking out or taking a severe course....

New Drug Mix From ICR And The Royal Marsden Shows Promise

The findings of a phase 1 trial examining a medication mixture targeting multiple mutant variants of cancer's 'death star' protein have been released by the Institute of Cancer Research (ICR) in London and The Royal Marsden NHS Foundation Trust. In...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read